Pub Date : 2025-12-16DOI: 10.1038/s41587-025-02924-1
{"title":"Targeting glycans for cancer immunotherapy.","authors":"","doi":"10.1038/s41587-025-02924-1","DOIUrl":"https://doi.org/10.1038/s41587-025-02924-1","url":null,"abstract":"","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":" ","pages":""},"PeriodicalIF":41.7,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145768629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-16DOI: 10.1038/s41587-025-02884-6
Jessica C Stark, Melissa A Gray, Itziar Ibarlucea-Benitez, Marta Lustig, Annalise Bond, Brian Cho, Ishika Govil, Tran Luu, Megan J Priestley, Tim S Veth, Wesley J Errington, Bence Bruncsics, Mikaela K Ribi, Leo A Williams, Casim A Sarkar, Simon Wisnovsky, Nicholas M Riley, Meghan A Morrissey, Thomas Valerius, Jeffrey V Ravetch, Carolyn R Bertozzi
Despite the curative potential of checkpoint blockade immunotherapy, many patients remain unresponsive to existing treatments. Glyco-immune checkpoints, which involve interactions of cell-surface glycans with lectin, or glycan-binding, immunoreceptors, have emerged as prominent mechanisms of immune evasion and therapeutic resistance in cancer. Here, we describe antibody-lectin chimeras (AbLecs), a modular system for glyco-immune checkpoint blockade. AbLecs are bispecific antibody-like molecules comprising a cell-targeting antibody domain and a lectin 'decoy receptor' domain that directly binds glycans and blocks their ability to engage inhibitory lectin receptors. AbLecs potentiate cancer cell destruction by primary human immune cells in vitro and reduce tumour burden in a humanized, immunocompetent mouse model, outperforming most existing therapies and combinations tested. By targeting a distinct axis of immunological regulation, AbLecs synergize with blockade of established immune checkpoints. AbLecs can be readily designed to target numerous tumours and immune cell subsets as well as glyco-immune checkpoints, thus representing a potential modality for cancer immunotherapy.
{"title":"Antibody-lectin chimeras for glyco-immune checkpoint blockade.","authors":"Jessica C Stark, Melissa A Gray, Itziar Ibarlucea-Benitez, Marta Lustig, Annalise Bond, Brian Cho, Ishika Govil, Tran Luu, Megan J Priestley, Tim S Veth, Wesley J Errington, Bence Bruncsics, Mikaela K Ribi, Leo A Williams, Casim A Sarkar, Simon Wisnovsky, Nicholas M Riley, Meghan A Morrissey, Thomas Valerius, Jeffrey V Ravetch, Carolyn R Bertozzi","doi":"10.1038/s41587-025-02884-6","DOIUrl":"https://doi.org/10.1038/s41587-025-02884-6","url":null,"abstract":"<p><p>Despite the curative potential of checkpoint blockade immunotherapy, many patients remain unresponsive to existing treatments. Glyco-immune checkpoints, which involve interactions of cell-surface glycans with lectin, or glycan-binding, immunoreceptors, have emerged as prominent mechanisms of immune evasion and therapeutic resistance in cancer. Here, we describe antibody-lectin chimeras (AbLecs), a modular system for glyco-immune checkpoint blockade. AbLecs are bispecific antibody-like molecules comprising a cell-targeting antibody domain and a lectin 'decoy receptor' domain that directly binds glycans and blocks their ability to engage inhibitory lectin receptors. AbLecs potentiate cancer cell destruction by primary human immune cells in vitro and reduce tumour burden in a humanized, immunocompetent mouse model, outperforming most existing therapies and combinations tested. By targeting a distinct axis of immunological regulation, AbLecs synergize with blockade of established immune checkpoints. AbLecs can be readily designed to target numerous tumours and immune cell subsets as well as glyco-immune checkpoints, thus representing a potential modality for cancer immunotherapy.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":" ","pages":""},"PeriodicalIF":41.7,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145768674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1038/s41587-025-02958-5
{"title":"Biotech news from around the world","authors":"","doi":"10.1038/s41587-025-02958-5","DOIUrl":"10.1038/s41587-025-02958-5","url":null,"abstract":"","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"43 12","pages":"1897-1897"},"PeriodicalIF":41.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145719873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1038/s41587-025-02953-w
Recent moves of note in and around the biotech and pharma industries.
生物技术和制药行业的最新动向。
{"title":"People","authors":"","doi":"10.1038/s41587-025-02953-w","DOIUrl":"10.1038/s41587-025-02953-w","url":null,"abstract":"Recent moves of note in and around the biotech and pharma industries.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"43 12","pages":"2078-2078"},"PeriodicalIF":41.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145719875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1038/s41587-025-02913-4
Paige E. Erpf, Felix Meier, Roy S. K. Walker, Hugh D. Goold, Jef D. Boeke, Ian T. Paulsen, Isak S. Pretorius
The Synthetic Yeast Genome Project (Sc2.0) set out to redesign and chemically synthesize an entire eukaryotic genome. This Comment summarizes the design- and construction-related defects revealed during the construction of 16 synthetic chromosomes, and the solutions applied, drawing out the key biological and technical insights that will inform future genome-scale engineering.
{"title":"Building synthetic chromosomes one yeast at a time: insights from Sc2.0","authors":"Paige E. Erpf, Felix Meier, Roy S. K. Walker, Hugh D. Goold, Jef D. Boeke, Ian T. Paulsen, Isak S. Pretorius","doi":"10.1038/s41587-025-02913-4","DOIUrl":"10.1038/s41587-025-02913-4","url":null,"abstract":"The Synthetic Yeast Genome Project (Sc2.0) set out to redesign and chemically synthesize an entire eukaryotic genome. This Comment summarizes the design- and construction-related defects revealed during the construction of 16 synthetic chromosomes, and the solutions applied, drawing out the key biological and technical insights that will inform future genome-scale engineering.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"43 12","pages":"1911-1918"},"PeriodicalIF":41.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145719863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1038/s41587-025-02935-y
Mateo Aboy, Kathleen Liddell, Cristina Crespo, Matthew Jordan, Stuart Hogarth, John Powell
After two decades of sustained growth, cancer diagnostics patents peaked in 2020 and have since stabilized, with a broad set of public and private players driving innovation.
{"title":"Mapping the patent landscape of cancer diagnostics","authors":"Mateo Aboy, Kathleen Liddell, Cristina Crespo, Matthew Jordan, Stuart Hogarth, John Powell","doi":"10.1038/s41587-025-02935-y","DOIUrl":"10.1038/s41587-025-02935-y","url":null,"abstract":"After two decades of sustained growth, cancer diagnostics patents peaked in 2020 and have since stabilized, with a broad set of public and private players driving innovation.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"43 12","pages":"1921-1928"},"PeriodicalIF":41.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145719874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号